This Article Full Text Full Text (PDF) All Versions of this Article: 44/1/61    most recent 01.HYP.0000133249.28773.d7v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, M. P. Articles by Schmieder, R. E. Search for Related Content PubMed PubMed Citation Articles by Schneider, M. P. Articles by Schmieder, R. E. Related Collections Cardiovascular Pharmacology Hypertrophy Electrocardiology Echocardiography

(Hypertension. 2004;44:61.)
© 2004 American Heart Association, Inc.

Scientific Contributions

Effect of Irbesartan Versus Atenolol on Left Ventricular Mass and Voltage

Results of the CardioVascular Irbesartan Project

Markus P. Schneider; Arnfried U. Klingbeil; Christian Delles; Malte Ludwig; Rainer E. Kolloch; Michael Krekler; Klaus O. Stumpe; Roland E. Schmieder

From the Department of Medicine IV/Nephrology (M.P.S., A.U.K., C.D., M.K., R.E.S.), University of Erlangen-Nürnberg, Germany; Department of Medicine (M.L., K.O.S.), University of Bonn, Germany; and the Department of Medicine (R.E.K.), Gilead Medical Center, Germany.

Correspondence to Prof. Dr. med. Roland E. Schmieder, Universität Erlangen-Nürnberg, Medizinische Klinik IV/4, Klinikum Nürnberg Süd Breslauer Straße 201, D-90471 Nürnberg, Germany. E-mail roland.schmieder{at}rzmail.uni-erlangen.de

Regression of hypertensive left ventricular hypertrophy (LVH) is associated with improved prognosis. The aim of this trial was to compare the effects of irbesartan versus atenolol on LVH in subjects with essential hypertension. Because electrocardiographic and echocardiographic parameters of LVH carry disparate prognostic information, both methods were applied in this trial. In the randomized, double-blind, multicenter trial CardioVascular Irbesartan Project, 240 patients with essential hypertension were treated with irbesartan or atenolol for 18 months. Voltage criteria used for LVH were Sokolow index, Cornell index, Cornell voltagexQRS duration product and Lewis index. In parallel, left ventricular mass (LVM) was determined by 2-dimensional guided M-mode echocardiography. After 6 and 18 months, reductions of LVM and voltage criteria for LVH were only found in subjects treated with irbesartan. However, a reduction of LVM was only detectable in subjects within the highest quartile of baseline LVM but not overall. In contrast, reductions of voltage criteria for LVH were detectable after 6 and 18 months even within commonly used normal limits. In conclusion, treatment of hypertension with irbesartan resulted in a significant reduction in the voltage criteria for LVH, although an effect on LVM was only seen in subjects with high baseline LVM. In contrast, atenolol did not lead to reductions in electrocardiographic or echocardiographic parameters of LVH. Because voltage criteria for LVH have been shown to predict cardiovascular outcome independently from LVM, we suggest that both methods should be used to accurately assess the benefits of antihypertensive treatment.

Key Words: hypertension, essential • hypertrophy • electrocardiography • echocardiography • drug therapy

This article has been cited by other articles:

				R. H. Fagard, H. Celis, L. Thijs, and S. Wouters Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies Hypertension, November 1, 2009; 54(5): 1084 - 1091. [Abstract] [Full Text] [PDF]

				P. M. Okin, E. Gerdts, S. E. Kjeldsen, S. Julius, J. M. Edelman, B. Dahlof, R. B. Devereux, and for the Losartan Intervention for Endpoint Reducti Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy Hypertension, July 1, 2008; 52(1): 100 - 106. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]

				V. Barrios, C. Escobar, A. Calderon, J. Pablo Tomas, S. Ruiz, J. L. Moya, A. Megias, O. Vegazo, and R. Fernandez Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice The VIPE study Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 236 - 242. [Abstract] [PDF]

				A. Delgado-Almeida, M. P. Schneider, R. E. Schmieder, R. H. Fagard, and on behalf of the Syst-Eur investigators Critical Value of the Electrocardiogram in LVH: From Predictive Index to Therapeutic Reassessment Hypertension, February 1, 2005; 45(2): e6 - e7. [Full Text] [PDF]